Efficacy and safety profiles are considerations when moving from acute to chronic treatment for schizophrenia

At ECNP 2022, Professor Christoph Correll chatted about how both efficacy and safety profiles are important when choosing a medication in the acute phases of schizophrenia. However, as it is likely that the first medication choice for a patient with schizophrenia is the one they will remain on once stabilised, it’s important to choose one that can be used long-term and also review the choice once a patient is stable. Professor Correll also discussed how the relationship between plasma levels of an antipsychotic, it’s clinical efficacy and safety are not always linear and may depend on the individual patient. The high peak/trough variability with oral medications may be avoided by using a long-acting injectable antipsychotic. Such medications can also aid adherence.

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country